DERM
NASDAQ · Pharmaceuticals
Journey Medical Corp
$7.31
-0.05 (-0.68%)
Financial Highlights (FY 2026)
Revenue
70.49M
Net Income
-13,026,549
Gross Margin
66.2%
Profit Margin
-18.5%
Rev Growth
-5.7%
D/E Ratio
0.79
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 66.2% | 66.2% | 62.4% | 62.4% |
| Operating Margin | -13.2% | -11.9% | 16.9% | 16.2% |
| Profit Margin | -18.5% | -17.6% | 17.9% | 16.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 70.49M | 74.72M | 106.46M | 91.38M |
| Gross Profit | 46.65M | 49.44M | 66.48M | 57.06M |
| Operating Income | -9,312,126 | -8,883,732 | 17.94M | 14.85M |
| Net Income | -13,026,549 | -12,427,278 | 19.04M | 15.46M |
| Gross Margin | 66.2% | 66.2% | 62.4% | 62.4% |
| Operating Margin | -13.2% | -11.9% | 16.9% | 16.2% |
| Profit Margin | -18.5% | -17.6% | 17.9% | 16.9% |
| Rev Growth | -5.7% | -5.7% | +23.5% | +18.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 45.52M | 45.52M | 81.05M | 98.09M |
| Total Equity | 57.36M | 57.36M | 109.66M | 130.87M |
| D/E Ratio | 0.79 | 0.79 | 0.74 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -4,461,300 | -4,492,511 | 19.03M | 16.26M |
| Free Cash Flow | — | — | 11.82M | 11.85M |